Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Date : du 13/08/2017 au 13/08/2021
  • Active substance : azacitidine
  • Type : Medicine
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Diseases and conditions (1)
  • Plus ...
    • Blood and lymphatic diseases (1)
    • Plus ...
      • Hematologic cancers (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Language
  • Français (1)
Active substance
  • azacitidine (1)
  • « Première page
  • < Page précédente
  • / 1
  • > Page suivante
  • » Dernière page
Sorted by :Relevance
  • Title
  • Date

  • VIDAZA (azacitidine), antimétabolite

    Medicine - Posted on 04/10/2017 - Mis à jour le 12/6/2019
    Add to my selection
  • « Première page
  • < Page précédente
  • / 1
  • > Page suivante
  • » Dernière page
  • 10 par pages
    • 10 par pages
    • 20 par pages
    • 50 par pages
    • 100 par pages
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
nqwHqQduKHWkZkVG